
|Articles|October 1, 2005
NSAID approved for cataract pain
After a priority 6-month review, the FDA approved nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories), a novel nonsteroidal anti-inflammatory prodrug, for the treatment of pain and inflammation associated with cataract surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region
2
Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial
3
AAVantgarde Bio closes $141 million Series B financing round
4


















































.png)


